Kadimastem, Merck deal

Kadimastem and Merck’s Merck Serono S.A. division expanded a 2012 deal to use Kadimastem’s stem cell-based, drug screening platform to discover compounds to treat multiple sclerosis (MS) and other neurodegenerative diseases. Under the expanded deal, Kadimastem will screen compounds from Merck using assays based on stem cell-derived astrocytes. Kadimastem will receive an undisclosed upfront fee and is eligible for milestones. The companies said financial terms are not disclosed. ...